Association Between Oral Antidiabetic with Unaprpopriate Drug and Microvascular and Macrovascular Complications: An Observational Study
Keywords:
Type 2 Diabetes Mellitus, Polypharmacy, Oral antidiabetic drug, Microvascular complication, Macrovascular complicationAbstract
Type 2 Diabetes Mellitus (T2DM) is associated with microvascular complications (retinopathy, neuropathy, nephropathy) and macrovascular complications (coronary artery disease, stroke), which contribute significantly to morbidity and mortality. Polypharmacy in the use of Oral Antidiabetic Drugs (OADs) may influence the occurrence of these complications through drug interactions and increased therapeutic complexity. A cross-sectional observational study was conducted involving 100 patients with T2DM. Data were collected from medical records. Variables included the level of OAD polypharmacy and the incidence of complications. Statistical analysis was performed using Spearman rank correlation test. The distribution of complications was 30.8% microvascular, 22.5% macrovascular, and 46.7% other complications. Spearman analysis demonstrated a statistically significant correlation between OAD polypharmacy and the incidence of complications (p=0.017), with a positive correlation of weak-to-moderate strength. OAD polypharmacy is associated with an increased risk of complications in T2DM patients. These findings highlight the importance of rational prescribing and regular therapeutic monitoring to minimize adverse outcomes.
Downloads
References
1. Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., ... & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice, 183, 109119. doi: 10.1016/j.diabres.2021.109119.
2. Wells, A., Reeves, D., Capobianco, L., Heal, C., Davies, L., Heagerty, A., ... & Fisher, P. (2021). Improving the effectiveness of psychological interventions for depression and anxiety in cardiac rehabilitation: PATHWAY—a single-blind, parallel, randomized, controlled trial of group metacognitive therapy. Circulation, 144(1), 23-33. doi: 10.1161/CIRCULATIONAHA.120.052428.
3. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., ... & Weiss, R. (2015). Type 2 diabetes mellitus. Nature reviews Disease primers, 1(1), 15019. doi: 10.1038/s41572-026-00687-w.
4. Rankin, A., Cadogan, C. A., Patterson, S. M., Kerse, N., Cardwell, C. R., Bradley, M. C., ... & Hughes, C. (2018). Interventions to improve the appropriate use of polypharmacy for older people. Cochrane database of systematic reviews, (9). doi: 10.1002/14651858.CD008165.pub4.
5. Delara, M., Murray, L., Jafari, B., Bahji, A., Goodarzi, Z., Kirkham, J., ... & Seitz, D. P. (2022). Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC geriatrics, 22(1), 601. doi: 10.1186/s12877-022-03279-x.
6. EAlexander, E. K., Doherty, G. M., & Barletta, J. A. (2022). Management of thyroid nodules. The Lancet Diabetes & Endocrinology, 10(7), 540-548. doi: 10.1016/S2213-8587(22)00139-5.
7. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., ... & Ruilope, L. M. (2021). Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New England Journal of Medicine, 385(24), 2252-2263. doi: 10.1056/NEJMoa2110956.
8. Dapagliflozin in Patients with Chronic Kidney Disease,” New England Journal of Medicine, vol. 383, no. 15, pp. 1436–1446, doi: 10.1056/NEJMoa2024816
9. Hauwanga, W. N., Abdalhamed, T. Y., Ezike, L. A., Chukwulebe, I. S., Oo, A. K., Wilfred, A., ... & Khan, A. R. A. K. (2024). The pathophysiology and vascular complications of diabetes in chronic kidney disease: A comprehensive review. Cureus, 16(12). doi: 10.7759/cureus.76498
10. Nong, K., Jeppesen, B. T., Shi, Q., Agoritsas, T., Guyatt, G. H., White, H., ... & Li, S. (2025). Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. bmj, 390. 10.1136/bmj-2024-083039
11. Wen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., ... & Zhou, L. (2025). The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials. BMC Endocrine Disorders, 25(1), 179. 10.1186/s12902-025-01985-2.
12. Duncan, B. B., Magliano, D. J., & Boyko, E. J. (2026). IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050. Nephrology Dialysis Transplantation, 41(1), 7-9.
13. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., ... & Buse, J. B. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 65(12), 1925-1966. 10.1007/s00125-022-05787-2
14. Alexander, E. K., & Cibas, E. S. (2022). Diagnosis of thyroid nodules. The lancet Diabetes & endocrinology, 10(7), 533-539. 10.1016/S2213-8587(22)00139-5
15. Grunberg, V. A., Geller, P. A., Durham, K., Bonacquisti, A., & Barkin, J. L. (2022). Motherhood and me (mom-me): The development of an acceptance-based group for women with postpartum mood and anxiety symptoms. Journal of clinical medicine, 11(9), 2345. 10.3390/jcm11092345
16. AL-Musawe, L., Ismael, A. H., & AL-Mukhtar, E. J. (2024). Optimizing polypharmacy in elderly with diabetes through routine benefit–risk assessment. Aging Research, 2(2), 9340038. 10.26599/AGR.2025.9340038.
